NCT05217381 (RosHER) is a clinical trial in Early Breast Cancer, sponsored by MedSIR.

Who is sponsoring NCT05217381?

NCT05217381 is sponsored by MedSIR.

What condition does NCT05217381 study?

NCT05217381 studies Early Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer.

Is NCT05217381 still recruiting?

NCT05217381 is currently completed. Last updated 25 September 2023.

Last reviewed 2023-09-25 · How we verify

NCT05217381: RosHER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status

Completed Last updated 25 September 2023

What this trial tests

trial in Early Breast Cancer in 18,533 participants. Completed in 20 September 2023.

Timeline

22 February 2022

Primary endpoint
20 September 2023

20 September 2023

Quick facts

Lead sponsor	MedSIR
Status	Completed
Study type	OBSERVATIONAL
Enrollment	18,533
Start date	22 February 2022
Primary completion	20 September 2023
Estimated completion	20 September 2023
Sites	7 locations across Spain

Conditions studied

Early Breast Cancer — all drugs for Early Breast Cancer →
Metastatic Breast Cancer — all drugs for Metastatic Breast Cancer →
Locally Advanced Breast Cancer — all drugs for Locally Advanced Breast Cancer →

Sponsor

MedSIR — full company profile →

Who can join

18 and older, any sex, with Early Breast Cancer or Metastatic Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a data-driven, retrospective, longitudinal, population- based, observational, multi-centered study using secondary data captured from congruent electronic health records (EHRs).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Human epidermal growth factor receptor 2 (HER2) expression dynamics between diagnosis and recurrence in patients with breast cancer using artificial intelligence and electronic health records: the RosHER study.
López-Miranda E, Tolosa-Ortega P, Perelló-Martorell MA, Sánchez-Lorenzo L, et al · · 2025 · cited 1× · PMID 41647339 · DOI 10.1016/j.esmorw.2024.100107

Verify or expand the search:

Other recruiting trials for Early Breast Cancer

Currently open trials in the same condition.

NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc · NA · recruiting
NCT07327021 — MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC · Phase 2 · recruiting
NCT06984250 — Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer · recruiting
NCT06650423 — Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer · recruiting
NCT05827081 — Phase IIIb Study of Ribociclib + ET in Early Breast Cancer · Phase 3 · recruiting

Other MedSIR trials

Trials by the same sponsor.

NCT07494448 — Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer · Phase 1, PHASE2 · not yet recruiting
NCT07178938 — Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases · Phase 2 · not yet recruiting
NCT05708235 — A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population · Phase 2 · recruiting
NCT05659563 — Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% · Phase 2 · completed
NCT05520723 — Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05217381 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MedSIR
Last refreshed: 25 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05217381.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing